Shelton Capital Management Takes Position in R1 RCM Inc. (NASDAQ:RCM)

Shelton Capital Management bought a new stake in R1 RCM Inc. (NASDAQ:RCM) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 217,094 shares of the healthcare provider’s stock, valued at approximately $4,005,000. Shelton Capital Management owned 0.05% of R1 RCM as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Parkside Financial Bank & Trust boosted its position in shares of R1 RCM by 67.2% in the 1st quarter. Parkside Financial Bank & Trust now owns 2,972 shares of the healthcare provider’s stock valued at $45,000 after purchasing an additional 1,195 shares during the period. Rhumbline Advisers lifted its position in R1 RCM by 1.4% during the 1st quarter. Rhumbline Advisers now owns 478,625 shares of the healthcare provider’s stock worth $7,179,000 after acquiring an additional 6,501 shares during the period. Pier 88 Investment Partners LLC lifted its position in R1 RCM by 36.0% during the 1st quarter. Pier 88 Investment Partners LLC now owns 105,780 shares of the healthcare provider’s stock worth $1,587,000 after acquiring an additional 27,990 shares during the period. Twin Tree Management LP acquired a new stake in R1 RCM during the 1st quarter worth approximately $2,984,000. Finally, Voss Capital LLC lifted its position in R1 RCM by 374.1% during the 1st quarter. Voss Capital LLC now owns 814,403 shares of the healthcare provider’s stock worth $12,216,000 after acquiring an additional 642,613 shares during the period. 61.10% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Evercore ISI decreased their price objective on R1 RCM from $21.00 to $20.00 in a research report on Wednesday, October 11th. Guggenheim reissued a “buy” rating and issued a $21.00 price target on shares of R1 RCM in a report on Friday, July 21st. Truist Financial raised R1 RCM from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a report on Thursday, October 19th. Cantor Fitzgerald initiated coverage on R1 RCM in a report on Tuesday, August 15th. They issued an “overweight” rating and a $20.00 price target for the company. Finally, Royal Bank of Canada reduced their price target on R1 RCM from $22.00 to $19.00 and set an “outperform” rating for the company in a report on Friday, November 3rd. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, R1 RCM currently has an average rating of “Moderate Buy” and a consensus price target of $18.97.

R1 RCM Price Performance

Shares of NASDAQ:RCM opened at $10.67 on Friday. The company has a market cap of $4.47 billion, a P/E ratio of -118.54, a P/E/G ratio of 60.44 and a beta of 0.86. The company has a quick ratio of 1.80, a current ratio of 1.90 and a debt-to-equity ratio of 0.60. R1 RCM Inc. has a 52 week low of $7.13 and a 52 week high of $18.70. The business has a fifty day simple moving average of $13.06 and a 200-day simple moving average of $15.62.

R1 RCM Profile

R1 RCM Inc provides technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and physician groups. It offers end-to-end revenue cycle management (RCM) services, which address the spectrum of revenue cycle challenges faced by healthcare providers.